查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2021 - 2031 年抗肥胖药物市场规模及预测、全球及地区份额、趋势及成长机会分析报告，涵盖：按类型、药物类别、应用、给药途径、配销通路和地理划分
市场调查报告书
商品编码
1761154

2021 - 2031 年抗肥胖药物市场规模及预测、全球及地区份额、趋势及成长机会分析报告，涵盖：按类型、药物类别、应用、给药途径、配销通路和地理划分

Anti-obesity Drugs Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Drug Class, Application, Route of Administration, and Distribution Channel, and Geography
出版日期: | 出版商: The Insight Partners | 英文 316 Pages | 订单完成后即时交付

价格

根据我们最新的研究报告《2031年抗肥胖药物市场预测－全球分析－按类型、药物类别、给药途径、应用、配销通路和地理划分》，预计该市场规模将从2024年的158.5亿美元增长到2031年的1772.7亿美元；预计2025-20亿美元增长到2031年的1772.7亿美元；预计2025-2031年期间的复合年增长率为3%。肥胖症的日益普及以及人们对体重管理解决方案的认识和需求的不断提高，正在推动抗肥胖药物市场规模的不断增长。然而，副作用和安全问题阻碍了抗肥胖药物市场的成长。此外，精准医疗和个人化抗肥胖药物治疗方案预计将在未来几年带来新的抗肥胖药物市场趋势。

就收入而言，北美在 2024 年占据市场主导地位。据估计，在预测期内，它将占据全球市场的主导地位。美国是世界上最大的抗肥胖药物市场。与糖尿病相关的慢性伤口包括足部、静脉和压疮。根据《国际组织修復与再生期刊》，1% 的美国人口患有活动性或癒合的静脉溃疡。根据美国疾病管制与预防中心 (CDC) 发布的《2020 年国家糖尿病统计报告》，美国各年龄层有 3,420 万人患有糖尿病，每年约有 100 万名糖尿病患者患有足部溃疡，而 600-700 万名糖尿病患者一生中会患溃疡。因此，糖尿病和慢性伤口发生率的上升导致伤口敷料的需求增加，并有助于预测期内抗肥胖药物市场的成长。美国公司专注于透过采用有机和无机策略来扩大其影响力。 2021年10月，Medline Industries宣布投资7,750万美元在堪萨斯州建设新的配送中心。

减肥药市场分析

新兴经济体扩张为未来提供市场机会

根据 2023 年 7 月发表的《柳叶刀》研究，预计到 2050 年，印度将有约 4.5 亿个成年人超重或肥胖。 2021 年，全球被归类为超重或肥胖的成年人中有一半以上生活在印度，有 1.8 亿人受到影响；中国有 4.02 亿人；巴西有 8800 万人；俄罗斯有 7,100 万人；墨西哥有 5,800 万人；印尼有 5,200 万人；埃及有 4100 万人；

根据世界肥胖联合会的数据，越南、印尼和孟加拉的肥胖盛行率正在上升，近几十年来成长率达到6-9%。由于城市化、久坐不动的生活方式和饮食习惯的变化，新兴国家的肥胖盛行率不断上升，这增加了对抗肥胖药物的需求。很大一部分人口仍未得到诊断或治疗，这为製药公司提供了一个尚未完全渗透的市场，使其有机会推出新的疗法并扩大其覆盖范围。礼来公司正准备在2026年之前在印度、巴西和墨西哥推出其减肥和糖尿病药物tirzepatide（糖尿病药物Mounjaro和肥胖药物Zepbound）。

巴西正在加强医疗基础设施和肥胖管理项目，为新型抗肥胖药物的引进和报销创造有利环境。 2024年4月，巴西在圣保罗州奥托兰迪亚开设了一家实验室，专门生产糖尿病和肥胖症药物，其中包括Ozempic的活性成分利拉鲁肽。这家由EMS营运的工厂也将生产Ozempic的关键成分索马鲁肽，该成分的专利有效期至2026年3月，目前正接受巴西国家卫生监督局（ANVISA）的审查。该工厂投资6,000万巴西雷亚尔（约1,093万美元），是巴西首个此类工厂，将支持联邦政府的「健康经济产业综合体」计画。

根据世界经济论坛的数据，初期获取抗肥胖药物的管道可能仅限于私人市场和自付费用。不过，未来中等收入国家的保险保障和仿製药的出现，或许能提高这些药物的可及性。因此，不断上升的肥胖率、政府的支持性倡议以及产品创新预计将为新兴国家的市场创造未来的成长机会。

抗肥胖药物市场报告細項分析

有助于得出抗肥胖药物市场分析的关键部分是类型、药物类别、给药途径、应用和配销通路。

根据类型，减肥药市场分为处方药和非处方药。 2024年，处方药市场占有相对较大份额。

依药物类别，减肥药市场细分为GLP-1激动剂、脂肪酶抑制剂、MC4R激动剂等。 GLP-1激动剂在2024年占据了最大的市场份额。 GLP-1激动剂细分市场进一步细分为司美格鲁肽、利拉鲁肽和替泽帕肽。

根据应用，减肥药市场可分为抑制食慾、抑制脂肪吸收/消化酵素、促进代谢、合併用药。 2024年，抑制食慾类药物占据了最大的市场。

就给药途径而言，减肥药市场分为口服和注射两种。 2024年，口服药物占据市场主导地位。

根据配销通路，减肥药市场可分为医院药房、线上通路和零售药房。 2024年，医院药局占据了市场主导地位。

抗肥胖药物市场：竞争格局与关键发展

Novo Nordisk AS、Eli Lilly and Co、GSK Plc、Rhythm Pharmaceuticals Inc、Currax Pharmaceuticals LLC.、VIVUS LLC、AdvaCare Pharma USA LL、Teva Pharmaceutical Industries Ltd、Sun Pharmaceutical Industries Ltd 和 F. Hoffmann-La Roche Ltd 是抗肥胖药物市场的主要公司。

世界卫生组织、世界肥胖地图集、美国食品药物管理局、柳叶刀杂誌、世界肥胖联合会、世界经济论坛、疾病管制与预防中心 (CDC)、国际糖尿病联盟 (IDF)、经济合作暨发展组织 (OECD) 是编写抗肥胖药物市场报告时参考的主要和次要来源。

目录

第一章：简介

第二章：执行摘要

  • 分析师市场展望

第三章：研究方法

  • 二次研究
  • 初步研究
    • 假设表述：
    • 宏观经济因素分析：
    • 显影基数：
    • 数据三角测量：
    • 国家级资料：
  • 假设和局限性

第四章：抗肥胖药物市场格局

  • 概述
  • PEST分析

第五章：抗肥胖药物市场－关键市场动态

  • 抗肥胖药物市场－关键市场动态
  • 市场驱动因素
    • 肥胖症日益普遍
    • 人们对体重管理解决方案的认识和需求不断提高
  • 市场限制
    • 副作用和安全问题
  • 市场机会
    • 新兴经济体的扩张
  • 未来趋势
    • 精准医疗和个人化抗肥胖药物治疗方案
  • 驱动因素和限制因素的影响：

第六章：抗肥胖药物市场－全球市场分析

  • 2021-2031年抗肥胖药物市场收入
  • 抗肥胖药物市场预测分析

第七章：抗肥胖药物市场分析－依类型

  • 处方药
  • 非处方药

第 8 章：抗肥胖药物市场分析 - 按药物类别

  • GLP-1激动剂
  • 脂肪酶抑制剂
  • MC4R激动剂
  • 其他的

第九章：抗肥胖药物市场分析－依应用

  • 抑制食慾
  • 抑制脂肪吸收或消化酶
  • 代谢增强
  • 组合

第 10 章：抗肥胖药物市场分析 - 按给药途径

  • 口服
  • 肠外

第 11 章：抗肥胖药物市场分析 - 按配销通路

  • 医院药房
  • 线上通路
  • 零售药局

第 12 章：抗肥胖药物市场 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿拉伯聯合大公国
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第十三章：产业格局

  • 概述
  • 新产品开发/核准
  • 其他商业策略

第 14 章：公司简介

  • Novo Nordisk AS
  • Eli Lilly and Co
  • GSK Plc
  • Rhythm Pharmaceuticals Inc
  • Currax Pharmaceuticals LLC.
  • VIVUS LLC
  • AdvaCare Pharma USA LLC
  • Teva Pharmaceutical Industries Ltd
  • Sun Pharmaceutical Industries Ltd
  • F. Hoffmann-La Roche Ltd

第 15 章：附录

Product Code: TIPRE00006850

According to our new research study on "Anti-obesity Drugs Market Forecast to 2031 -Global Analysis - by Type, Drug Class, Route of Administration, Application, Distribution Channel, and Geography," the market is anticipated to grow from US$ 15.85 billion in 2024 and is projected to reach US$ 177.27 billion by 2031; it is expected to register a CAGR of 35.3% during 2025-2031. Mounting prevalence of obesity and increased awareness and demand for weight management solutions are contributing to the growing anti-obesity drugs market size. However, the side effects and safety concerns hamper the anti-obesity drugs market growth. Further, precision medicine and personalized anti-obesity drug regimens is expected to bring in new anti-obesity drugs market trends in the coming years.

In terms of revenue, North America dominated the market in 2024. It is estimated to dominate the global market during the forecast period. The US is the largest market for anti-obesity drugs in the world. Chronic wounds associated with diabetes include foot, venous, and pressure ulcers. According to The International Journal of Tissue Repair and Regeneration, active or healed venous ulcers occur in 1% of the US population. As per the National Diabetes Statistics Report 2020, a publication of the Centers for Disease Control and Prevention (CDC), 34.2 million people of all ages in the US have diabetes, and ~1 million diabetics develop a foot ulcer each year, while 6-7 million diabetes patients develop ulcers in their lifetime. Thus, the rising incidence of diabetes and chronic wounds leads to an increase in demand for wound dressing and contributes to the anti-obesity drugs market growth during the forecast period. Companies in the US are focused on expanding their presence by adopting organic and inorganic strategies. In October 2021, Medline Industries announced an investment of US$ 77.5 million to build a new distribution center in Kansas.

Anti-obesity Drugs Market Analysis

Expansion in Emerging Economies to Provide Market Opportunities in Future

According to a Lancet study published in July 2023, approximately 450 million adults in India are expected to be overweight or obese by 2050. In 2021, more than half of the world's adults who were classified as overweight or obese lived in India, with 180 million affected individuals; China, with 402 million; Brazil, with 88 million; Russia, with 71 million; Mexico, with 58 million; Indonesia, with 52 million; and Egypt, with 41 million.

According to the World Obesity Federation, Vietnam, Indonesia, and Bangladesh are experiencing rising obesity prevalence, with a rate of 6-9% in recent decades. The mounting prevalence of obesity in emerging countries due to urbanization, sedentary lifestyles, and dietary changes has increased the demand for anti-obesity drugs. A large segment of the population remains undiagnosed or untreated, offering an underpenetrated market for pharmaceutical companies to introduce new therapies and expand their reach. Eli Lilly is preparing to launch its weight-loss and diabetes drug, tirzepatide (marketed as Mounjaro for diabetes and Zepbound for obesity), in India, Brazil, and Mexico by 2026.

Brazil is enhancing healthcare infrastructure and obesity management programs, fostering a supportive environment for the introduction and reimbursement of new anti-obesity medications. In April 2024, Brazil opened a laboratory in Hortolandia, Sao Paulo State, dedicated to producing medications for diabetes and obesity, including liraglutide, an active ingredient found in Ozempic. The EMS-operated plant will also produce semaglutide, a key ingredient in Ozempic, which has a patent valid until March 2026 and is already under review by Agencia Nacional de Vigilancia Sanitaria (ANVISA). With an investment of R$60 million (~US$ 10.93 million), this facility is the first of its kind in Brazil and supports the federal government's Health Economic-Industrial Complex initiatives.

According to the World Economic Forum, initial access to anti-obesity medications may be limited to private markets and out-of-pocket payments. Still, future insurance coverage and generic versions in middle-income countries could improve the accessibility of these medications. Thus, the rising obesity rates, supportive government initiatives, and product innovations are expected to create future growth opportunities for the market in emerging countries.

Anti-obesity Drugs Market Report Segmentation Analysis

Key segments that contributed to the derivation of the anti-obesity drugs market analysis are type, drug class, route of administration, application, and distribution channel.

Based on type, the anti-obesity drugs market is bifurcated into prescription and OTC. The prescription segment held relatively larger share of the market in 2024.

By drug class, the anti-obesity drugs market is segmented into GLP-1 agonists, lipase inhibitors, MC4R agonists, and others. The GLP-1 Agonist segment held the largest share of the market in 2024. GLP-1 agonists segment further subsegmented into Semaglutide, Liraglutide, Tirzepatide.

Based on application, the anti-obesity drugs market is categorized into appetite suppression, inhibition of fat absorption/digestive enzymes, metabolic enhancement, and combination. The appetite suppression segment held a largest share of the market in 2024.

In terms of route of administration, the anti-obesity drugs market is bifurcated into oral and parenteral. The oral segment dominated the market in 2024.

Per distribution channel, the anti-obesity drugs market is categorized into hospital pharmacies, online channel, and retail pharmacies. The hospital pharmacies segment dominated the market in 2024.

Anti-obesity Drugs Market: Competitive Landscape and Key Developments

Novo Nordisk AS, Eli Lilly and Co, GSK Plc, Rhythm Pharmaceuticals Inc, Currax Pharmaceuticals LLC., VIVUS LLC, AdvaCare Pharma USA LL, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, and F. Hoffmann-La Roche Ltd are among the key companies operating in the anti-obesity drugs market.

The World Health Organization, World Obesity Atlas, The U.S. Food and Drug Administration, The Lancet Journal, World Obesity Federation, World Economic Forum, Centers for Disease Control and Prevention (CDC), the International Diabetes Federation (IDF), the Organization for Economic Co-operation and Development (OECD) are primary and secondary sources referred to while preparing the anti-obesity drugs market report.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Analyst Market Outlook

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:
  • 3.3 Assumptions and Limitations

4. Anti-Obesity Drugs Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Anti-Obesity Drugs Market - Key Market Dynamics

  • 5.1 Anti-Obesity Drugs Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Mounting Prevalence of Obesity
    • 5.2.2 Increased Awareness and Demand for Weight Management Solutions
  • 5.3 Market Restraints
    • 5.3.1 Side Effects and Safety Concerns
  • 5.4 Market Opportunities
    • 5.4.1 Expansion in Emerging Economies
  • 5.5 Future Trends
    • 5.5.1 Precision Medicine and Personalized Anti-Obesity Drug Regimens
  • 5.6 Impact of Drivers and Restraints:

6. Anti-Obesity Drugs Market - Global Market Analysis

  • 6.1 Anti-Obesity Drugs Market Revenue (US$ Million), 2021-2031
  • 6.2 Anti-Obesity Drugs Market Forecast Analysis

7. Anti-Obesity Drugs Market Analysis - by Type

  • 7.1 Prescription Drugs
    • 7.1.1 Overview
    • 7.1.2 Prescription Drugs: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 OTC Drugs
    • 7.2.1 Overview
    • 7.2.2 OTC Drugs: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)

8. Anti-Obesity Drugs Market Analysis - by Drug Class

  • 8.1 GLP-1 Agonist
    • 8.1.1 Overview
    • 8.1.2 GLP-1 Agonist: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Lipase Inhibitors
    • 8.2.1 Overview
    • 8.2.2 Lipase Inhibitors: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 MC4R agonist
    • 8.3.1 Overview
    • 8.3.2 MC4R agonist: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Others
    • 8.4.1 Overview
    • 8.4.2 Others: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)

9. Anti-Obesity Drugs Market Analysis - by Application

  • 9.1 Appetite Suppression
    • 9.1.1 Overview
    • 9.1.2 Appetite Suppression: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Inhibition of Fat Absorption or Digestive Enzymes
    • 9.2.1 Overview
    • 9.2.2 Inhibition of Fat Absorption or Digestive Enzymes: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Metabolic Enhancement
    • 9.3.1 Overview
    • 9.3.2 Metabolic Enhancement: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.4 Combination
    • 9.4.1 Overview
    • 9.4.2 Combination: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)

10. Anti-Obesity Drugs Market Analysis - by Route Of Administration

  • 10.1 Oral
    • 10.1.1 Overview
    • 10.1.2 Oral: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2 Parenteral
    • 10.2.1 Overview
    • 10.2.2 Parenteral: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)

11. Anti-Obesity Drugs Market Analysis - by Distribution Channel

  • 11.1 Hospital Pharmacies
    • 11.1.1 Overview
    • 11.1.2 Hospital Pharmacies: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 11.2 Online Channel
    • 11.2.1 Overview
    • 11.2.2 Online Channel: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 11.3 Retail Pharmacies
    • 11.3.1 Overview
    • 11.3.2 Retail Pharmacies: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)

12. Anti-Obesity Drugs Market - Geographical Analysis

  • 12.1 Overview
  • 12.2 North America
    • 12.2.1 North America Anti-Obesity Drugs Market Overview
    • 12.2.2 North America: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
    • 12.2.3 North America: Anti-Obesity Drugs Market Breakdown, by Type
      • 12.2.3.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Type
    • 12.2.4 North America: Anti-Obesity Drugs Market Breakdown, by Drug Class
      • 12.2.4.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Drug Class
        • 12.2.4.1.1 North America: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    • 12.2.5 North America: Anti-Obesity Drugs Market Breakdown, by Application
      • 12.2.5.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Application
    • 12.2.6 North America: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
      • 12.2.6.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
    • 12.2.7 North America: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.2.7.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
    • 12.2.8 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
      • 12.2.8.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
      • 12.2.8.2 United States: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.2.8.2.1 United States: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.2.8.2.2 United States: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.2.8.2.2.1 United States: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.2.8.2.3 United States: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.2.8.2.4 United States: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.2.8.2.5 United States: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.2.8.3 Canada: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.2.8.3.1 Canada: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.2.8.3.2 Canada: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.2.8.3.2.1 Canada: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.2.8.3.3 Canada: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.2.8.3.4 Canada: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.2.8.3.5 Canada: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.2.8.4 Mexico: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.2.8.4.1 Mexico: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.2.8.4.2 Mexico: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.2.8.4.2.1 Mexico: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.2.8.4.3 Mexico: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.2.8.4.4 Mexico: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.2.8.4.5 Mexico: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  • 12.3 Europe
    • 12.3.1 Europe Anti-Obesity Drugs Market Overview
    • 12.3.2 Europe: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
    • 12.3.3 Europe: Anti-Obesity Drugs Market Breakdown, by Type
      • 12.3.3.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Type
    • 12.3.4 Europe: Anti-Obesity Drugs Market Breakdown, by Drug Class
      • 12.3.4.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Drug Class
        • 12.3.4.1.1 Europe: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    • 12.3.5 Europe: Anti-Obesity Drugs Market Breakdown, by Application
      • 12.3.5.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Application
    • 12.3.6 Europe: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
      • 12.3.6.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
    • 12.3.7 Europe: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.3.7.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
    • 12.3.8 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
      • 12.3.8.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
      • 12.3.8.2 Germany: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.3.8.2.1 Germany: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.3.8.2.2 Germany: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.3.8.2.2.1 Germany: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.3.8.2.3 Germany: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.3.8.2.4 Germany: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.3.8.2.5 Germany: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.3.8.3 United Kingdom: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.3.8.3.1 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.3.8.3.2 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.3.8.3.2.1 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.3.8.3.3 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.3.8.3.4 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.3.8.3.5 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.3.8.4 France: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.3.8.4.1 France: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.3.8.4.2 France: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.3.8.4.2.1 France: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.3.8.4.3 France: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.3.8.4.4 France: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.3.8.4.5 France: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.3.8.5 Spain: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.3.8.5.1 Spain: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.3.8.5.2 Spain: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.3.8.5.2.1 Spain: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.3.8.5.3 Spain: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.3.8.5.4 Spain: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.3.8.5.5 Spain: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.3.8.6 Italy: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.3.8.6.1 Italy: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.3.8.6.2 Italy: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.3.8.6.2.1 Italy: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.3.8.6.3 Italy: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.3.8.6.4 Italy: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.3.8.6.5 Italy: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.3.8.7 Rest of Europe: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.3.8.7.1 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.3.8.7.2 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.3.8.7.2.1 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.3.8.7.3 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.3.8.7.4 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.3.8.7.5 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  • 12.4 Asia Pacific
    • 12.4.1 Asia Pacific Anti-Obesity Drugs Market Overview
    • 12.4.2 Asia Pacific: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
    • 12.4.3 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Type
      • 12.4.3.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Type
    • 12.4.4 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Drug Class
      • 12.4.4.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Drug Class
        • 12.4.4.1.1 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    • 12.4.5 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Application
      • 12.4.5.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Application
    • 12.4.6 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
      • 12.4.6.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
    • 12.4.7 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.4.7.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
    • 12.4.8 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
      • 12.4.8.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
      • 12.4.8.2 China: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.4.8.2.1 China: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.4.8.2.2 China: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.4.8.2.2.1 China: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.4.8.2.3 China: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.4.8.2.4 China: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.4.8.2.5 China: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.4.8.3 Japan: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.4.8.3.1 Japan: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.4.8.3.2 Japan: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.4.8.3.2.1 Japan: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.4.8.3.3 Japan: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.4.8.3.4 Japan: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.4.8.3.5 Japan: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.4.8.4 India: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.4.8.4.1 India: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.4.8.4.2 India: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.4.8.4.2.1 India: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.4.8.4.3 India: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.4.8.4.4 India: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.4.8.4.5 India: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.4.8.5 Australia: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.4.8.5.1 Australia: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.4.8.5.2 Australia: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.4.8.5.2.1 Australia: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.4.8.5.3 Australia: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.4.8.5.4 Australia: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.4.8.5.5 Australia: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.4.8.6 South Korea: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.4.8.6.1 South Korea: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.4.8.6.2 South Korea: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.4.8.6.2.1 South Korea: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.4.8.6.3 South Korea: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.4.8.6.4 South Korea: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.4.8.6.5 South Korea: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.4.8.7 Rest of APAC: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.4.8.7.1 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.4.8.7.2 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.4.8.7.2.1 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.4.8.7.3 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.4.8.7.4 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.4.8.7.5 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  • 12.5 Middle East and Africa
    • 12.5.1 Middle East and Africa Anti-Obesity Drugs Market Overview
    • 12.5.2 Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
    • 12.5.3 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Type
      • 12.5.3.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Type
    • 12.5.4 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Drug Class
      • 12.5.4.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Drug Class
        • 12.5.4.1.1 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    • 12.5.5 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Application
      • 12.5.5.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Application
    • 12.5.6 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
      • 12.5.6.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
    • 12.5.7 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.5.7.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
    • 12.5.8 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
      • 12.5.8.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
      • 12.5.8.2 Saudi Arabia: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.5.8.2.1 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.5.8.2.2 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.5.8.2.2.1 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.5.8.2.3 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.5.8.2.4 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.5.8.2.5 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.5.8.3 South Africa: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.5.8.3.1 South Africa: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.5.8.3.2 South Africa: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.5.8.3.2.1 South Africa: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.5.8.3.3 South Africa: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.5.8.3.4 South Africa: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.5.8.3.5 South Africa: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.5.8.4 United Arab Emirates: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.5.8.4.1 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.5.8.4.2 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.5.8.4.2.1 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.5.8.4.3 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.5.8.4.4 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.5.8.4.5 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.5.8.5 Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.5.8.5.1 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.5.8.5.2 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.5.8.5.2.1 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.5.8.5.3 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.5.8.5.4 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.5.8.5.5 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  • 12.6 South and Central America
    • 12.6.1 South and Central America Anti-Obesity Drugs Market Overview
    • 12.6.2 South and Central America: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
    • 12.6.3 South and Central America: Anti-Obesity Drugs Market Breakdown, by Type
      • 12.6.3.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Type
    • 12.6.4 South and Central America: Anti-Obesity Drugs Market Breakdown, by Drug Class
      • 12.6.4.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Drug Class
        • 12.6.4.1.1 South and Central America: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    • 12.6.5 South and Central America: Anti-Obesity Drugs Market Breakdown, by Application
      • 12.6.5.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Application
    • 12.6.6 South and Central America: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
      • 12.6.6.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
    • 12.6.7 South and Central America: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.6.7.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
    • 12.6.8 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
      • 12.6.8.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
      • 12.6.8.2 Brazil: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.6.8.2.1 Brazil: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.6.8.2.2 Brazil: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.6.8.2.2.1 Brazil: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.6.8.2.3 Brazil: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.6.8.2.4 Brazil: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.6.8.2.5 Brazil: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.6.8.3 Argentina: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.6.8.3.1 Argentina: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.6.8.3.2 Argentina: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.6.8.3.2.1 Argentina: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.6.8.3.3 Argentina: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.6.8.3.4 Argentina: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.6.8.3.5 Argentina: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.6.8.4 Rest of South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.6.8.4.1 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.6.8.4.2 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.6.8.4.2.1 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.6.8.4.3 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.6.8.4.4 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.6.8.4.5 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Distribution Channel

13. Industry Landscape

  • 13.1 Overview
  • 13.2 New Product Development/Approval
  • 13.3 Other Business Strategies

14. Company Profiles

  • 14.1 Novo Nordisk AS
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
  • 14.2 Eli Lilly and Co
    • 14.2.1 Key Facts
    • 14.2.2 Business Description
    • 14.2.3 Products and Services
    • 14.2.4 Financial Overview
    • 14.2.5 SWOT Analysis
    • 14.2.6 Key Developments
  • 14.3 GSK Plc
    • 14.3.1 Key Facts
    • 14.3.2 Business Description
    • 14.3.3 Products and Services
    • 14.3.4 Financial Overview
    • 14.3.5 SWOT Analysis
  • 14.4 Rhythm Pharmaceuticals Inc
    • 14.4.1 Key Facts
    • 14.4.2 Business Description
    • 14.4.3 Products and Services
    • 14.4.4 Financial Overview
    • 14.4.5 SWOT Analysis
    • 14.4.6 Key Developments
  • 14.5 Currax Pharmaceuticals LLC.
    • 14.5.1 Key Facts
    • 14.5.2 Business Description
    • 14.5.3 Products and Services
    • 14.5.4 Financial Overview
    • 14.5.5 SWOT Analysis
    • 14.5.6 Key Developments
  • 14.6 VIVUS LLC
    • 14.6.1 Key Facts
    • 14.6.2 Business Description
    • 14.6.3 Products and Services
    • 14.6.4 Financial Overview
    • 14.6.5 SWOT Analysis
    • 14.6.6 Key Developments
  • 14.7 AdvaCare Pharma USA LLC
    • 14.7.1 Key Facts
    • 14.7.2 Business Description
    • 14.7.3 Products and Services
    • 14.7.4 Financial Overview
    • 14.7.5 SWOT Analysis
  • 14.8 Teva Pharmaceutical Industries Ltd
    • 14.8.1 Key Facts
    • 14.8.2 Business Description
    • 14.8.3 Products and Services
    • 14.8.4 Financial Overview
    • 14.8.5 SWOT Analysis
  • 14.9 Sun Pharmaceutical Industries Ltd
    • 14.9.1 Key Facts
    • 14.9.2 Business Description
    • 14.9.3 Products and Services
    • 14.9.4 Financial Overview
    • 14.9.5 SWOT Analysis
    • 14.9.6 Key Developments
  • 14.10 F. Hoffmann-La Roche Ltd
    • 14.10.1 Key Facts
    • 14.10.2 Business Description
    • 14.10.3 Products and Services
    • 14.10.4 Financial Overview
    • 14.10.5 SWOT Analysis

15. Appendix

  • 15.1 About The Insight Partners
  • 15.2 Glossary of Terms

List Of Tables

  • Table 1. Anti-Obesity Drugs Market Segmentation
  • Table 2. Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million)
  • Table 3. Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million)
  • Table 4. Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 5. Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 6. Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 7. Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 8. Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 9. Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 10. Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 11. Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 12. Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 13. Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 14. Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 15. Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 16. North America: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 17. North America: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 18. North America: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 19. North America: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 20. North America: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 21. North America: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 22. North America: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 23. North America: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 24. North America: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 25. North America: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 26. North America: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 27. North America: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 28. North America: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Country
  • Table 29. North America: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Country
  • Table 30. United States: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 31. United States: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 32. United States: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 33. United States: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 34. United States: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 35. United States: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 36. United States: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 37. United States: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 38. United States: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 39. United States: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 40. United States: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 41. United States: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 42. Canada: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 43. Canada: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 44. Canada: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 45. Canada: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 46. Canada: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 47. Canada: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 48. Canada: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 49. Canada: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 50. Canada: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 51. Canada: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 52. Canada: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 53. Canada: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 54. Mexico: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 55. Mexico: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 56. Mexico: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 57. Mexico: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 58. Mexico: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 59. Mexico: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 60. Mexico: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 61. Mexico: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 62. Mexico: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 63. Mexico: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 64. Mexico: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 65. Mexico: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 66. Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 67. Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 68. Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 69. Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 70. Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 71. Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 72. Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 73. Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 74. Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 75. Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 76. Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 77. Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 78. Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Country
  • Table 79. Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Country
  • Table 80. ADULT OBESITY IN 2030
  • Table 81. CHILD OBESITY IN 2030
  • Table 82. Germany: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 83. Germany: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 84. Germany: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 85. Germany: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 86. Germany: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 87. Germany: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 88. Germany: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 89. Germany: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 90. Germany: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 91. Germany: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 92. Germany: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 93. Germany: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 94. United Kingdom: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 95. United Kingdom: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 96. United Kingdom: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 97. United Kingdom: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 98. United Kingdom: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 99. United Kingdom: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 100. United Kingdom: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 101. United Kingdom: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 102. United Kingdom: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 103. United Kingdom: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 104. United Kingdom: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 105. United Kingdom: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 106. France: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 107. France: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 108. France: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 109. France: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 110. France: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 111. France: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 112. France: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 113. France: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 114. France: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 115. France: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 116. France: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 117. France: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 118. ADULT OBESITY IN 2030
  • Table 119. CHILD OBESITY IN 2030
  • Table 120. Spain: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 121. Spain: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 122. Spain: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 123. Spain: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 124. Spain: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 125. Spain: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 126. Spain: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 127. Spain: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 128. Spain: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 129. Spain: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 130. Spain: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 131. Spain: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 132. Italy: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 133. Italy: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 134. Italy: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 135. Italy: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 136. Italy: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 137. Italy: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 138. Italy: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 139. Italy: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 140. Italy: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 141. Italy: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 142. Italy: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 143. Italy: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 144. Rest of Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 145. Rest of Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 146. Rest of Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 147. Rest of Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 148. Rest of Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 149. Rest of Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 150. Rest of Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 151. Rest of Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 152. Rest of Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 153. Rest of Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 154. Rest of Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 155. Rest of Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 156. Asia Pacific: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 157. Asia Pacific: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 158. Asia Pacific: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 159. Asia Pacific: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 160. Asia Pacific: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 161. Asia Pacific: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 162. Asia Pacific: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 163. Asia Pacific: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 164. Asia Pacific: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 165. Asia Pacific: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 166. Asia Pacific: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 167. Asia Pacific: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 168. Asia Pacific: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Country
  • Table 169. Asia Pacific: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Country
  • Table 170. China: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 171. China: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 172. China: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 173. China: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 174. China: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 175. China: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 176. China: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 177. China: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 178. China: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 179. China: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 180. China: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 181. China: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 182. ADULT OBESITY IN 2030
  • Table 183. CHILD OBESITY IN 2030
  • Table 184. Japan: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 185. Japan: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 186. Japan: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 187. Japan: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 188. Japan: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 189. Japan: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 190. Japan: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 191. Japan: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 192. Japan: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 193. Japan: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 194. Japan: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 195. Japan: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 196. India: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 197. India: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 198. India: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 199. India: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 200. India: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 201. India: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 202. India: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 203. India: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 204. India: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 205. India: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 206. India: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 207. India: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 208. Australia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 209. Australia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 210. Australia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 211. Australia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 212. Australia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 213. Australia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 214. Australia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 215. Australia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 216. Australia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 217. Australia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 218. Australia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 219. Australia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 220. South Korea: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 221. South Korea: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 222. South Korea: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 223. South Korea: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 224. South Korea: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 225. South Korea: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 226. South Korea: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 227. South Korea: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 228. South Korea: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 229. South Korea: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 230. South Korea: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 231. South Korea: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 232. Rest of APAC: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 233. Rest of APAC: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 234. Rest of APAC: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 235. Rest of APAC: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 236. Rest of APAC: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 237. Rest of APAC: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 238. Rest of APAC: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 239. Rest of APAC: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 240. Rest of APAC: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 241. Rest of APAC: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 242. Rest of APAC: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 243. Rest of APAC: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 244. Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 245. Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 246. Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 247. Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 248. Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 249. Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 250. Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 251. Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 252. Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 253. Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 254. Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 255. Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 256. Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Country
  • Table 257. Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Country
  • Table 258. Saudi Arabia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 259. Saudi Arabia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 260. Saudi Arabia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 261. Saudi Arabia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 262. Saudi Arabia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 263. Saudi Arabia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 264. Saudi Arabia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 265. Saudi Arabia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 266. Saudi Arabia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 267. Saudi Arabia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 268. Saudi Arabia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 269. Saudi Arabia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 270. ADULT OBESITY IN 2030
  • Table 271. CHILD OBESITY IN 2030
  • Table 272. South Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 273. South Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 274. South Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 275. South Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 276. South Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 277. South Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 278. South Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 279. South Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 280. South Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 281. South Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 282. South Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 283. South Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 284. United Arab Emirates: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 285. United Arab Emirates: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 286. United Arab Emirates: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 287. United Arab Emirates: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 288. United Arab Emirates: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 289. United Arab Emirates: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 290. United Arab Emirates: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 291. United Arab Emirates: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 292. United Arab Emirates: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 293. United Arab Emirates: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 294. United Arab Emirates: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 295. United Arab Emirates: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 296. ADULT OBESITY IN 2030
  • Table 297. CHILD OBESITY IN 2030
  • Table 298. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 299. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 300. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 301. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 302. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 303. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 304. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 305. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 306. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 307. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 308. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 309. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 310. South and Central America: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 311. South and Central America: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 312. South and Central America: Anti-Obesity Drugs Market - Revenue, 20

List Of Figures

  • Figure 1. Anti-Obesity Drugs Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Anti-Obesity Drugs Market Revenue (US$ Million), 2021-2031
  • Figure 5. Anti-Obesity Drugs Market Share (%) - by Type (2024 and 2031)
  • Figure 6. Prescription Drugs: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. OTC Drugs: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Anti-Obesity Drugs Market Share (%) - by Drug Class (2024 and 2031)
  • Figure 9. GLP-1 Agonist: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Lipase Inhibitors: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. MC4R agonist: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Others: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Anti-Obesity Drugs Market Share (%) - by Application (2024 and 2031)
  • Figure 14. Appetite Suppression: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Inhibition of Fat Absorption or Digestive Enzymes: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Metabolic Enhancement: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Combination: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Anti-Obesity Drugs Market Share (%) - by Route Of Administration (2024 and 2031)
  • Figure 19. Oral: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. Parenteral: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Anti-Obesity Drugs Market Share (%) - by Distribution Channel (2024 and 2031)
  • Figure 22. Hospital Pharmacies: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. Online Channel: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Retail Pharmacies: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. Anti-Obesity Drugs Market Breakdown by Region, 2024 and 2031 (%)
  • Figure 26. North America: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
  • Figure 27. North America: Anti-Obesity Drugs Market Breakdown, by Type (2024 and 2031)
  • Figure 28. North America: Anti-Obesity Drugs Market Breakdown, by Drug Class (2024 and 2031)
  • Figure 29. North America: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist (2024 and 2031)
  • Figure 30. North America: Anti-Obesity Drugs Market Breakdown, by Application (2024 and 2031)
  • Figure 31. North America: Anti-Obesity Drugs Market Breakdown, by Route Of Administration (2024 and 2031)
  • Figure 32. North America: Anti-Obesity Drugs Market Breakdown, by Distribution Channel (2024 and 2031)
  • Figure 33. North America: Anti-Obesity Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 34. United States: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 35. Canada: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 36. Mexico: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 37. Europe: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
  • Figure 38. Europe: Anti-Obesity Drugs Market Breakdown, by Type (2024 and 2031)
  • Figure 39. Europe: Anti-Obesity Drugs Market Breakdown, by Drug Class (2024 and 2031)
  • Figure 40. Europe: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist (2024 and 2031)
  • Figure 41. Europe: Anti-Obesity Drugs Market Breakdown, by Application (2024 and 2031)
  • Figure 42. Europe: Anti-Obesity Drugs Market Breakdown, by Route Of Administration (2024 and 2031)
  • Figure 43. Europe: Anti-Obesity Drugs Market Breakdown, by Distribution Channel (2024 and 2031)
  • Figure 44. Europe: Anti-Obesity Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 45. Germany: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 46. United Kingdom: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 47. France: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 48. Spain: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 49. Italy: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 50. Rest of Europe: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 51. Asia Pacific: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
  • Figure 52. Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Type (2024 and 2031)
  • Figure 53. Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Drug Class (2024 and 2031)
  • Figure 54. Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist (2024 and 2031)
  • Figure 55. Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Application (2024 and 2031)
  • Figure 56. Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Route Of Administration (2024 and 2031)
  • Figure 57. Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Distribution Channel (2024 and 2031)
  • Figure 58. Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 59. China: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 60. Japan: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 61. India: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 62. Australia: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 63. South Korea: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 64. Rest of APAC: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 65. Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
  • Figure 66. Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Type (2024 and 2031)
  • Figure 67. Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Drug Class (2024 and 2031)
  • Figure 68. Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist (2024 and 2031)
  • Figure 69. Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Application (2024 and 2031)
  • Figure 70. Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Route Of Administration (2024 and 2031)
  • Figure 71. Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Distribution Channel (2024 and 2031)
  • Figure 72. Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 73. Saudi Arabia: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 74. South Africa: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 75. United Arab Emirates: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 76. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 77. South and Central America: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
  • Figure 78. South and Central America: Anti-Obesity Drugs Market Breakdown, by Type (2024 and 2031)
  • Figure 79. South and Central America: Anti-Obesity Drugs Market Breakdown, by Drug Class (2024 and 2031)
  • Figure 80. South and Central America: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist (2024 and 2031)
  • Figure 81. South and Central America: Anti-Obesity Drugs Market Breakdown, by Application (2024 and 2031)
  • Figure 82. South and Central America: Anti-Obesity Drugs Market Breakdown, by Route Of Administration (2024 and 2031)
  • Figure 83. South and Central America: Anti-Obesity Drugs Market Breakdown, by Distribution Channel (2024 and 2031)
  • Figure 84. South and Central America: Anti-Obesity Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 85. Brazil: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 86. Argentina: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 87. Rest of South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)